Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction

American Journal of Medicine

Volumn 120, Issue 2, 2007, Pages 109-120

  Gheorghiade, Mihai ^a   Fonarow, Gregg C ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Neurohormonal antagonists; Post MI management; Systolic dysfunction

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; PERINDOPRIL; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; TICLOPIDINE; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; WARFARIN; ZOFENOPRIL;

ALGORITHM; CLINICAL TRIAL; COMORBIDITY; DEFIBRILLATOR; DRUG WITHDRAWAL; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE; HEART VENTRICLE ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SYSTOLIC DYSFUNCTION; TREATMENT INDICATION;

HUMANS; MYOCARDIAL INFARCTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33846618606     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.08.010     Document Type: Review

References (60)

1. American Heart Association. Heart Disease and Stroke Statistics-2005 Update (2005), American Heart Association, Dallas, TX
2. Steg P.G., Dabbous O.H., Feldman L.J., et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 109 (2004) 494-499
3. Amiodarone Trials Meta- Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta- Analysis Investigators. Lancet 350 (1997) 1417-1424
4. Kober L., Torp-Pedersen C., Carlsen J.E., et al., Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
5. Kober L., Torp-Pedersen C., Jorgensen S., et al., TRACE Study Group. Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. Trandolapril Cardiac Evaluation. Am J Cardiol 81 (1998) 1292-1297
6. Klein L., and Gheorghiade M. Coronary artery disease and prevention of heart failure. Med Clin North Am 88 (2004) 1209-1235
7. Fonarow G.C., Abraham W.T., Cannon C.P., et al. Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. Rev Cardiovasc Med 4 Suppl 3 (2003) S54-S59
8. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 110 (2004) 588-636
9. Hasdai D., Topol E.J., Kilaru R., et al. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J 145 (2003) 73-79
10. Velazquez E.J., Francis G.S., Armstrong P.W., et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J 25 (2004) 1911-1919
11. Solomon S.D., Zelenkofske S., McMurray J.J., et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352 (2005) 2581-2588
12. Bolognese L., Neskovic A.N., Parodi G., et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 106 (2002) 2351-2357
13. Gheorghiade M., and Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97 (1998) 282-289
14. Yusuf S., Peto R., Lewis J., et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985) 335-371
15. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 97 (1998) 2202-2212
16. Ryan T.J., Antman E.M., Brooks N.H., et al. 1999 update: ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 100 (1999) 1016-1030
17. Pfeffer M.A., Braunwald E., Moye L.A., et al., The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992) 669-677
18. AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342 (1993) 821-828
19. Torp-Pedersen C., Kober L., and TRACE Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Trandolapril Cardiac Evaluation. Lancet 354 (1999) 9-12
20. Ambrosioni E., Borghi C., Magnani B., and The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332 (1995) 80-85
21. Borghi C., and Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 145 (2003) 80-87
22. Yusuf S., Sleight P., Pogue J., et al., The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. [published errata appear in N Engl J Med 2000 Mar 9;342:748 and 2000 May 4;342:1376]. N Engl J Med 342 (2000) 145-153
23. Fox K.A., Poole-Wilson P.A., Henderson R.A., et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 360 (2002) 743-751
24. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (2002) 752-760
25. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
26. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
27. Freemantle N., Cleland J., Young P., et al. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ 318 (1999) 1730-1737
28. McMurray J., Kober L., Robertson M., et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction. Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 (2005) 525-530
29. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
30. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 (2005) 425-431
31. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308 (1994) 81-106
32. Teo K.K., Yusuf S., Pfeffer M., et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 360 (2002) 1037-1043
33. Stenestrand U., and Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285 (2001) 430-436
34. Sacks F.M., Pfeffer M.A., Moye L.A., et al., Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
35. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
36. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
37. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
38. Kjekshus J., Pedersen T.R., Olsson A.G., et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
39. Julian D.G., Camm A.J., Frangin G., et al., European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 349 (1997) 667-674
40. Buxton A.E., Lee K.L., Fisher J.D., et al., Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341 (1999) 1882-1890
41. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
42. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
43. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 345 (1995) 669-685
44. GISSI-3 Investigators, and Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343 (1994) 1115-1122
45. Cleland J.G., Erhardt L., Murray G., et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 18 (1997) 41-51
46. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
47. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
48. Hjalmarson A., Elmfeldt D., Herlitz J., et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 2 (1981) 823-827
49. Hjalmarson A., Herlitz J., Holmberg S., et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 67 (1983) I26-I32
50. Herlitz J., Elmfeldt D., Holmberg S., et al. Goteborg Metoprolol Trial: mortality and causes of death. Am J Cardiol 53 (1984) 9D-14D
51. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction. Mortality. Am J Cardiol 56 (1985) 15G-22G
52. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2 (1986) 57-66
53. Roberts R., Rogers W.J., Mueller H.S., et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 83 (1991) 422-437
54. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J 8 (1987) 1056-1064
55. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304 (1981) 801-807
56. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247 (1982) 1707-1714
57. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 250 (1983) 2814-2819
58. COREG (carvedilol) Tablets [prescribing information pamphlet]. CO:L9 (2005), GlaxoSmithKline, Research Triangle Park, NC
59. Tavazzi L., Tognoni G., Franzosi M.G., et al., GISSI investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6 (2004) 635-641
60. Kjekshus J., Dunselman P.H., Blideskog M., et al., CORONA study Group. A statin in the treatment of heart failure?. Controlled rosuvastatin multinational study in the heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7 (2005) 1059-1069